...
首页> 外文期刊>Nanotechnology >Gold nanorod vaccine for respiratory syncytial virus
【24h】

Gold nanorod vaccine for respiratory syncytial virus

机译:呼吸道合胞病毒金纳米棒疫苗

获取原文
获取原文并翻译 | 示例

摘要

Respiratory syncytial virus (RSV) is a major cause of pneumonia and wheezing in infants and the elderly, but to date there is no licensed vaccine. We developed a gold nanorod construct that displayed the major protective antigen of the virus, the fusion protein (F). Nanorods conjugated to RSV F were formulated as a candidate vaccine preparation by covalent attachment of viral protein using a layer-by-layer approach. In vitro studies using ELISA, electron microscopy and circular dichroism revealed that conformation-dependent epitopes were maintained during conjugation, and transmission electron microscopy studies showed that a dispersed population of particles could be achieved. Human dendritic cells treated with the vaccine induced immune responses in primary human T cells. These results suggest that this vaccine approach may be a potent method for immunizing against viruses such as RSV with surface glycoproteins that are targets for the human immune response.
机译:呼吸道合胞病毒(RSV)是婴儿和老年人肺炎和喘息的主要原因,但是迄今为止,尚无许可的疫苗。我们开发了金纳米棒构建体,该构建体展示了病毒的主要保护性抗原,融合蛋白(F)。使用逐层方法通过共价附着病毒蛋白,将缀合到RSV F的纳米棒配制为候选疫苗制剂。使用ELISA,电子显微镜和圆二色性的体外研究表明,在缀合过程中可以维持构象依赖性表位,而透射电子显微镜研究表明可以实现分散的粒子群。用疫苗处理的人树突状细胞在原代人T细胞中诱导免疫应答。这些结果表明,这种疫苗方法可能是一种有效的方法,可利用表面糖蛋白(如人类免疫应答的靶标)针对诸如RSV的病毒进行免疫。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号